stockrowNexalin Technology, Inc.
NXLNexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024.
- Revenue
- −82.7%
- EPS
- −10.0%
- Free cash flow
- −97.2%
Quarter to June 2026, against a year earlier
Follow NXL
Alert me
Nexalin Technology, Inc. (NXL) EV/Sales
As of 6 November 2026, Nexalin Technology, Inc. (NXL) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −14.2× (October 2023) to 263× (December 2024); the current reading is higher than 24% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.0× | (86.18%) |
| FY2024 | 130× | — |
| FY2023 | −0.1× | — |
| FY2022 | −2.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 27.5× | 80.65% |
| Mar 2026 | 15.2× | (15.33%) |
| Dec 2025 | 18.0× | (76.42%) |
| Sep 2025 | 76.2× | 36.98% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICCM IceCure Medical Ltd. compare | −3.8× |
| CODX Co-Diagnostics, Inc. compare | −3.5× |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| BJDX Bluejay Diagnostics, Inc. compare | n/m |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| NXL Nexalin Technology, Inc. | 0.2× |
| IVF INVO Fertility, Inc compare | 0.2× |
| GCTK GlucoTrack, Inc. compare | 4.2× |
| ADGM Adagio Medical Holdings, Inc. compare | 30.6× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)